A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
AbbVie
Eli Lilly and Company
Hoffmann-La Roche
Amgen
Hoffmann-La Roche
EMD Serono
Norwegian University of Science and Technology
AbbVie
Qilu Pharmaceutical Co., Ltd.
Abramson Cancer Center at Penn Medicine
University of Sydney
Spanish Lung Cancer Group
Kalbe International Pte. Ltd
Helsinn Healthcare SA
Helsinn Healthcare SA
Sumitomo Pharma America, Inc.
Centus Biotherapeutics Limited
AbbVie
Clovis Oncology, Inc.
Shanghai University of Traditional Chinese Medicine
AbbVie
Daiichi Sankyo
Shanghai Gebaide Biotechnology Co., Ltd.
Amgen
Mario Negri Institute for Pharmacological Research
GlaxoSmithKline
INSYS Therapeutics Inc
Ontario Clinical Oncology Group (OCOG)
AstraZeneca
Hellenic Oncology Research Group
Ontario Clinical Oncology Group (OCOG)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hellenic Oncology Research Group
Hellenic Oncology Research Group
Pharmacyclics LLC.